Figure 3 | British Journal of Cancer

Figure 3

From: NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients

Figure 3

Three-year conditional overall and PFS experience of the total cohort ( n =539) according to pretreatment uric acid levels. The empirical cut-off at the 75th percentile (Q3) was used for this analysis. Patients with elevated pretreatment uric acid levels (⩾Q3) initially had a worse 3-year conditional progression- and OS experience, which improved over time, and approached the 3-year COS and 3-year CPFS experience of patients with uric acid levels

Back to article page